{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:38:55Z","timestamp":1785814735862,"version":"3.56.0"},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T00:00:00Z","timestamp":1065052800000},"content-version":"vor","delay-in-days":2740,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1996,4]]},"abstract":"<jats:p> <jats:bold>1<\/jats:bold>\u2003To determine whether dexfenfluramine is a substrate of cytochrome P450 2D6 (CYP2D6), its disposition has been studied in nine extensive (EM) and eight poor metabolizers (PM) of debrisoquine.<\/jats:p><jats:p> <jats:bold>2<\/jats:bold>\u2003Following a 30\u2003mg dose of dexfenfluramine hydrochloride, urine was collected in all subjects for 96\u2003h post\u2010dose and plasma samples were collected in 11 subjects (six EMs and five PMs). Dexfenfluramine and nordexfenfluramine were measured in urine by h.p.l.c. and in plasma by g.c.<\/jats:p><jats:p> <jats:bold>3<\/jats:bold>\u2003Urinary recovery of dexfenfluramine was greater in PMs than EMs (4136\u00b11509\u2003\u03bcg <jats:italic>vs<\/jats:italic> 1986\u00b1792\u2003\u03bcg; 95% CI of difference 926\u20133374; <jats:italic>P<\/jats:italic>&lt;0.05) whereas that of nordexfenfluramine was similar in both phenotypes (PM: 1753\u00b1411\u2003\u03bcg <jats:italic>vs<\/jats:italic> 1626\u00b1444\u2003\u03bcg).<\/jats:p><jats:p> <jats:bold>4<\/jats:bold>\u2003Dexfenfluramine AUC was higher in PMs (677\u00b1348\u2003\u03bcg l<jats:sup>\u22121<\/jats:sup> h) than EMs (359\u00b1250\u2003\u03bcg l<jats:sup>\u22121<\/jats:sup> h). The apparent oral clearance of dexfenfluramine was greater in EMs than PMs (93.6\u00b142.4 l h<jats:sup>\u22121<\/jats:sup><jats:italic>vs<\/jats:italic> 45.6\u00b119.5 l h<jats:sup>\u22121<\/jats:sup>; 95% CI of difference 1.2\u201394.7; <jats:italic>P<\/jats:italic>&lt;0.05). The renal clearance was similar in both phenotypes (EMs: 5.88\u00b12.83 l h<jats:sup>\u22121<\/jats:sup>; PMs 6.60\u00b12.01 l h<jats:sup>\u22121<\/jats:sup>), indicating that the higher urinary recovery of dexfenfluramine in PMs reflects higher plasma concentrations, rather than phenotype differences in the renal handling, of dexfenfluramine.<\/jats:p><jats:p> <jats:bold>5<\/jats:bold>\u2003The apparent nonrenal clearance of dexfenfluramine was substantially lower (<jats:italic>P<\/jats:italic>&lt;0.05; 95% CI of difference 3.0\u201394.1) in PMs (39.0\u00b119.5 l h<jats:sup>\u22121<\/jats:sup>) than EMs (87.6\u00b141.2 l h<jats:sup>\u22121<\/jats:sup>).<\/jats:p><jats:p> <jats:bold>6<\/jats:bold>\u2003There was a significant inverse correlation (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>=\u22120.776 95% CI \u22120.31\u2013\u22120.94; <jats:italic>n<\/jats:italic>=11; <jats:italic>P<\/jats:italic>=0.005) between the debrisoquine metabolic ratio and the apparent nonrenal clearance of dexfenfluramine.<\/jats:p><jats:p> <jats:bold>7<\/jats:bold>\u2003PMs had a higher incidence of adverse effects (nausea and vomiting) than EMs.<\/jats:p><jats:p> <jats:bold>8<\/jats:bold>\u2003In conclusion, the metabolism of dexfenfluramine is impaired in PMs. Thus CYP2D6, the isoenzyme deficient in poor metabolizers of debrisoquine, must catalyse at least one pathway of dexfenfluramine biotransformation.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1996.03178.x","type":"journal-article","created":{"date-parts":[[2003,10,14]],"date-time":"2003-10-14T16:08:23Z","timestamp":1066147703000},"page":"311-317","source":"Crossref","is-referenced-by-count":24,"title":["The influence of the sparteine\/debrisoquine genetic polymorphism on the disposition of dexfenfluramine"],"prefix":"10.1111","volume":"41","author":[{"given":"A. S.","family":"GROSS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"PHILLIPS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"RIEUTORD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"SHENFIELD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,2]]},"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1996.03178.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1996.03178.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1996.03178.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:36:34Z","timestamp":1694396194000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1996.03178.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["10.1046\/j.1365-2125.1996.03178.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1996.03178.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}